RecruitingPhase 2NCT05950594

IVIM & OLINK in Sarcoma

Prospective Study of Image and Blood-derived Biomarkers to Predict Metastasis in Soft-tissue Sarcomas


Sponsor

University Health Network, Toronto

Enrollment

145 participants

Start Date

Mar 5, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The hypoxia \> metastasis axis suggests that a DWI-based biomarker of hypoxia incorporating IVIM may be able to predict metastasis in STS patients, ultimately enabling stratification for personalized treatments at the time of diagnostic (MR) imaging, without adding an excessive burden to the patient or clinical workflow (typical DWI/IVIM sequences can be acquired acquired in approximately 5 minutes).


Eligibility

Min Age: 18 YearsMax Age: 100 Years

Inclusion Criteria3

  • Age ≥ 18 years
  • Ability to understand and the willingness to sign a written informed consent document
  • Grade 2 or 3 soft tissue sarcoma greater than 5 cm in largest dimension

Exclusion Criteria1

  • Contraindication to MRI scan as per current institutional guidelines (for patients requiring MRI)

Interventions

RADIATIONRadiotherapy

Standard of care pre-operative radiotherapy

OTHERSurgery

Standard of care definitive surgery


Locations(1)

University Health Network

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05950594


Related Trials